These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9256883)

  • 1. Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
    Kish JA; Wolf MK; Schellhammer PF; Hussain MH; Einstein AB; Crawford ED
    Am J Clin Oncol; 1997 Aug; 20(4):327-30. PubMed ID: 9256883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
    Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
    Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
    Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
    Kucuk O; Shevrin DH; Pandya KJ; Bonomi PD
    Am J Clin Oncol; 2000 Aug; 23(4):371-5. PubMed ID: 10955866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
    Ahmed S; Vaitkevicius VK; Zalupski MM; Du W; Arlauskas P; Gordon C; Kellogg C; Shields AF
    Am J Clin Oncol; 2000 Aug; 23(4):420-4. PubMed ID: 10955876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
    Bensmaine M el-A ; Guillot T; Bernal ET; Janot F; Sigal R; Domenge C; Wibault P; Armand JP; Cvitkovic E
    Am J Clin Oncol; 1996 Aug; 19(4):356-62. PubMed ID: 8677904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
    J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
    Alba E; Sanchez-Chaparro MA; Alonso L; Ribelles N; Ramon Delgado J; Rueda A; Pablo Tenllado P; Solano J; Urquiza R
    Am J Clin Oncol; 1996 Apr; 19(2):140-3. PubMed ID: 8610637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
    Kovács AF; Eberlein K; Hülsmann T
    Oral Maxillofac Surg; 2009 Jun; 13(2):87-93. PubMed ID: 19430823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
    Oh WK; Manola J; Richie JP; Loughlin KR; Kantoff PW
    Cancer; 1999 Oct; 86(7):1329-34. PubMed ID: 10506721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
    Faivre C; Rougier P; Ducreux M; Mitry E; Lusinchi A; Lasser P; Elias D; Eschwege F
    Bull Cancer; 1999 Oct; 86(10):861-5. PubMed ID: 10572237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment of invasive bladder carcinoma with transurethral resection, induction chemotherapy, and radical radiotherapy plus concomitant protracted infusion of cisplatin and 5-fluorouracil: a phase I study.
    Danesi DT; Arcangeli G; Cruciani E; Mecozzi A; Saracino B; Giacobini S; Pannunzio E; Biggio A; Orefici F
    Cancer; 1997 Oct; 80(8):1464-71. PubMed ID: 9338471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.